Monitor for any amendments to this 13D indicating a shift from passive to active stance, such as board representation demands or strategic review proposals. The 180-day lock-up expires around March 2027, after which OrbiMed's selling activity could pressure the stock.
Price Chart
Executive Summary
OrbiMed Advisors, a healthcare-focused investment firm, filed a Schedule 13D disclosing beneficial ownership of 6,885,170 shares (11.0%) of Electra Therapeutics, Inc. The stake was acquired through a series of preferred stock investments and IPO participation, with OrbiMed's Carl L. Gordon serving on Electra's board. The filing states the investment is passive with no current plans for control or major changes, but the 13D filing signals potential for future engagement.
Key Financial Metrics
Key Facts
- OrbiMed Advisors LLC and related entities hold 6,885,170 shares, representing 11.0% of Electra Therapeutics' outstanding common stock.
- The stake is held through two funds: OPI VII (5,126,891 shares, 8.2%) and Genesis (1,758,279 shares, 2.8%).
- Carl L. Gordon, a member of OrbiMed Advisors, serves on Electra's board of directors.
- Shares were acquired through conversion of Series A, B, and C preferred stock and IPO purchases at $15.00 per share.
- The filing states no current plans for control, mergers, asset sales, board changes, or other major corporate actions.
- Registration rights and a 180-day lock-up agreement are in place post-IPO.
Financial Impact
OrbiMed's total stake value is approximately $103.3 million based on the $15.00 IPO price, representing 11.0% ownership.
Risk Factors
- OrbiMed could increase its stake or seek changes in strategy, board composition, or capital allocation, creating uncertainty.
- Post-lock-up, OrbiMed may sell a portion of its 11% stake, potentially weighing on the stock.
- The filing's passive language may not preclude future activist engagement, especially given OrbiMed's board seat.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D Filing (Primary) | 0000947871-26-000898 |
| Document: 0000947871-26-000898-index-headers.html | 0000947871-26-000898 |
| Document: 0000947871-26-000898-index.html | 0000947871-26-000898 |
| Document: 0000947871-26-000898.txt | 0000947871-26-000898 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 28, 2026 28d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 25, 2026 4w ago | SC 13D | $11.32 $11.35 | ▲ +0.27% | ▲ +0.45% | $8.37 (−26.06%) |
Sep 23, 2026 4w ago | Insider Cluster | $11.82 $11.55 | ▼ −2.28% | ▼ −2.83% | $8.37 (−29.19%) |
Sep 21, 2026 5w ago | 3 | $13.62 $12.67 | ▼ −6.97% | ▼ −6.25% | $8.37 (−38.55%) |
Sep 18, 2026 5w ago | 424B4 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | EFFECT | $13.25 $13.92 | ▲ +5.06% | ▲ +3.51% | $8.37 (−36.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers